Literature DB >> 27220667

Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML.

H Wu1,2, A Wang1,2, Z Qi1,3, X Li1,3, C Chen1,3, K Yu1,2, F Zou1,3, C Hu1,2, W Wang1,3, Z Zhao1,3, J Wu1,2, J Liu1,3, X Liu1,2, L Wang1,3, W Wang1,3, S Zhang3,4, R M Stone5, I A Galinsky5, J D Griffin5, D Weinstock5, A Christodoulou5, H Wang6,7, Y Shen6,7, Z Zhai6,7, E L Weisberg5, J Liu1,3, Q Liu1,2,3,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27220667      PMCID： PMC5053879          DOI： 10.1038/leu.2016.151

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

Review 1.  Acute myeloid leukemia.

Authors:  B Löwenberg; J R Downing; A Burnett
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

2.  A small molecule-kinase interaction map for clinical kinase inhibitors.

Authors:  Miles A Fabian; William H Biggs; Daniel K Treiber; Corey E Atteridge; Mihai D Azimioara; Michael G Benedetti; Todd A Carter; Pietro Ciceri; Philip T Edeen; Mark Floyd; Julia M Ford; Margaret Galvin; Jay L Gerlach; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Michael A Insko; Andiliy G Lai; Jean-Michel Lélias; Shamal A Mehta; Zdravko V Milanov; Anne Marie Velasco; Lisa M Wodicka; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart
Journal:  Nat Biotechnol       Date:  2005-02-13       Impact factor: 54.908

3.  Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.

Authors:  Rehan Ahmad; Suiyang Liu; Ellen Weisberg; Erik Nelson; Ilene Galinsky; Colin Meyer; Donald Kufe; Surender Kharbanda; Richard Stone
Journal:  Mol Cancer Res       Date:  2010-06-22       Impact factor: 5.852

Review 4.  FLT-3: a new focus in the understanding of acute leukemia.

Authors:  Ana Markovic; Karen L MacKenzie; Richard B Lock
Journal:  Int J Biochem Cell Biol       Date:  2005-01-26       Impact factor: 5.085

5.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Authors:  Catherine C Smith; Qi Wang; Chen-Shan Chin; Sara Salerno; Lauren E Damon; Mark J Levis; Alexander E Perl; Kevin J Travers; Susana Wang; Jeremy P Hunt; Patrick P Zarrinkar; Eric E Schadt; Andrew Kasarskis; John Kuriyan; Neil P Shah
Journal:  Nature       Date:  2012-04-15       Impact factor: 49.962

6.  Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.

Authors:  H Wu; C Hu; A Wang; E L Weisberg; W Wang; C Chen; Z Zhao; K Yu; J Liu; J Wu; A Nonami; L Wang; B Wang; R M Stone; S Liu; J D Griffin; J Liu; Q Liu
Journal:  Leukemia       Date:  2015-07-03       Impact factor: 11.528

7.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Authors:  Patrick P Zarrinkar; Ruwanthi N Gunawardane; Merryl D Cramer; Michael F Gardner; Daniel Brigham; Barbara Belli; Mazen W Karaman; Keith W Pratz; Gabriel Pallares; Qi Chao; Kelly G Sprankle; Hitesh K Patel; Mark Levis; Robert C Armstrong; Joyce James; Shripad S Bhagwat
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

Review 8.  The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.

Authors:  Seth A Wander; Mark J Levis; Amir T Fathi
Journal:  Ther Adv Hematol       Date:  2014-06

9.  Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.

Authors:  Allison Galanis; Hayley Ma; Trivikram Rajkhowa; Abhijit Ramachandran; Donald Small; Jorge Cortes; Mark Levis
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113

10.  Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.

Authors:  Alexander A Warkentin; Michael S Lopez; Elisabeth A Lasater; Kimberly Lin; Bai-Liang He; Anskar Yh Leung; Catherine C Smith; Neil P Shah; Kevan M Shokat
Journal:  Elife       Date:  2014-12-22       Impact factor: 8.140
  10 in total
  4 in total

Review 1.  [Advances in targeted therapy for childhood acute myeloid leukemia].

Authors:  Ni-Na Wang; Qi-Dong Ye
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

2.  Molecular mechanisms by which splice modulator GEX1A inhibits leukaemia development and progression.

Authors:  Mark Sellin; Ryan Mack; Matthew C Rhodes; Lei Zhang; Stephanie Berg; Kanak Joshi; Shanhui Liu; Wei Wei; Peter Breslin S J; Peter Larsen; Richard E Taylor; Jiwang Zhang
Journal:  Br J Cancer       Date:  2022-04-14       Impact factor: 9.075

3.  A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?

Authors:  E Troadec; S Dobbelstein; P Bertrand; N Faumont; F Trimoreau; M Touati; J Chauzeix; B Petit; D Bordessoule; J Feuillard; C Bastard; N Gachard
Journal:  Leukemia       Date:  2016-10-31       Impact factor: 11.528

4.  Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT.

Authors:  Jaideep B Bharate; Nicholas McConnell; Gunaganti Naresh; Lingtian Zhang; Naga Rajiv Lakkaniga; Lucky Ding; Neil P Shah; Brendan Frett; Hong-Yu Li
Journal:  Sci Rep       Date:  2018-02-27       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.